Microvitality

What Microvitality does

Microvitality is a Massachusetts-based life sciences startup developing a novel capsule-based medical device for non-invasive sampling of the small intestine microbiome. Incorporated as Microvitality Inc. and operating with 1-10 employees, the company is headquartered in the Worcester/Boston corridor. Its core product is a swallowable capsule featuring pH-dependent enteric coating dissolution that activates only upon reaching the small intestine, combined with a proprietary self-locking mechanism that prevents contamination from downstream GI regions. The capsule enables fluid biopsy of the small intestine, addressing a documented gap in microbiome research where most studies rely on fecal sampling that only reflects the colon's terminal microbiota.

The technology is positioned around the small intestine's outsized physiological importance: the company cites that 90% of drug absorption occurs in this region, making it highly relevant for drug metabolism studies, immune regulation research, gut-brain axis investigations, and precision medicine applications. Microvitality markets the platform across biomarker discovery, host-microbiome research, diagnostics development, pharmacomicrobiomics profiling, gut-brain axis studies, and nutrition research — indicating a horizontal platform strategy rather than a single-application focus.

Microvitality operates an enterprise field sales motion targeting pharmaceutical companies, research institutions, diagnostics developers, and nutrition/food science organizations. Revenue mechanics span two streams: hardware sales of proprietary sampling capsules and related equipment, and professional services for biomarker discovery, host-microbiome research, and pharmacomicrobiomics profiling. No public pricing exists; engagement begins through a contact form on the company website, consistent with a consultative, partnership-driven sales process. The company received a $250,000 accelerator investment from the Auxilium-MBI Accelerator program in June 2026 as one of four healthcare startups selected, providing capital alongside mentorship and strategic planning support.

Name

Microvitality

Legal name

Microvitality Inc.

Website

https://microvitalitybio.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Microvitality develops a proprietary capsule-based medical device for non-invasive, uncontaminated fluid biopsy of the small intestine microbiome. The Boston-area startup serves pharmaceutical, research, diagnostics, and nutrition customers, enabling biomarker discovery and pharmacomicrobiomics research.

Ownership category

akta.pro rank

Product category

Medical Devices

NAICS

Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery) (HLAAAFAJ)

Keywords

• Microbiome sampling devices
• Small intestine diagnostics
• Capsule biopsy technology
• Pharmacomicrobiomics research
• Gastrointestinal medical devices

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

Revenue model

1. Capsule Technology Platform: Revenue derived from selling proprietary sampling capsules and related equipment to pharmaceutical companies and research institutions for microbiome research applications.
2. Research Services and Data: Partnership-based model providing biomarker discovery, host-microbiome research, diagnostics development, and pharmacomicrobiomics profiling services to pharmaceutical companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Microvitality develops and manufactures a proprietary capsule device that enables precise, non-invasive, and uncontaminated fluid biopsy sampling of the small intestine microbiome. The capsule uses pH-dependent enteric coating dissolution and a proprietary self-locking mechanism to bypass the stomach and prevent contamination, allowing pharmaceutical companies and research institutions to access small intestine microbiome data for biomarker discovery, pharmacomicrobiomics profiling, diagnostics, and nutrition research.

Product overview

Microvitality is a life sciences company developing a single core product: a novel capsule technology for small intestine microbiome sampling. The company operates a platform approach offering this capsule-based fluid biopsy solution across multiple research applications including biomarker discovery, host-microbiome research, diagnostics, nutrition research, and precision medicine (pharmacomicrobiomics profiling). Their technology enables pharmaceutical companies and research institutions to access small intestine microbiome data that was previously difficult to obtain due to the inaccessibility of this GI region.

Differentiator

Problem solved

Functional benefit

Products and services

• Microvitality Small Intestine Sampling Capsule A proprietary capsule device that performs precise, non-invasive, and uncontaminated fluid biopsy sampling of the small intestine microbiome. Features pH-dependent enteric coating dissolution that activates upon reaching the small intestine and a proprietary self-locking mechanism that prevents contamination from the large intestine. Sold to pharmaceutical companies, research institutions, diagnostics developers, and nutrition researchers for biomarker discovery, host-microbiome research, diagnostics, pharmacomicrobiomics profiling, and gut-brain axis studies.

Quantifiable outcome

• 90% of drug absorption occurs in the small intestine, making this region critical for drug metabolism research

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators1 record

Recent moves4 records

Expansion highlights4 records

Direct peers

• DayTwo: DayTwo provides microbiome-based personalized nutrition and gut health insights. It is comparable to Microvitality's nutrition/food science customer segment and shares a microbiome-data business model, though DayTwo uses stool-based sampling.
• Viome: Viome is a consumer and clinical microbiome testing company that monetizes gut microbiome data. Microvitality is comparable as a microbiome insights provider targeting pharma and research customers, though Viome relies on fecal sampling while Microvitality focuses on the small intestine.
• Thryve: Thryve is a microbiome testing and analytics company providing gut microbiome data services to researchers, consumer brands, and clinicians. It competes in the same microbiome data services category Microvitality targets with its research services offering.
• Medtronic (PillCam): Medtronic's PillCam is the leading ingestible capsule endoscopy platform, representing the closest direct peer in capsule-based GI sampling hardware. Microvitality's small intestine sampling capsule targets an adjacent niche (microbiome fluid biopsy) within the same ingestible-capsule category.
• Check Cap: Check Cap is developing an ingestible capsule for colorectal cancer screening using X-ray-based scanning. It is a direct peer as another ingestible diagnostic capsule developer with a similar device miniaturization and GI-access technology stack.
• Olympus (Endocapsule / Capsule Endoscopy): Olympus offers capsule endoscopy systems (e.g., Endocapsule) used to image the small intestine. While Olympus focuses on imaging rather than microbiome sampling, it is a direct peer in ingestible small intestine access technology.

Others

• CosmosID: CosmosID provides microbiome sequencing and bioinformatics services to researchers, clinicians, and industry. It is comparable as a microbiome data services and analytics infrastructure provider that Microvitality could partner with or compete against in microbiome insights delivery.

Emerging players

• Second Genome: Second Genome is a clinical-stage biotechnology company identifying and validating microbiome-derived drug targets and biomarkers. It overlaps with Microvitality's biomarker discovery and host-microbiome research service offerings.
• Vedanta Biosciences: Vedanta Biosciences is developing defined bacterial consortia as live biotherapeutic products, leveraging microbiome science and immunology expertise. It is an emerging player in the broader microbiome therapeutics space that could benefit from Microvitality's sampling capabilities.

Broad incumbents

• Seres Therapeutics: Seres Therapeutics is a clinical-stage microbiome therapeutics company working on defined consortia for GI and immune diseases. It is a broad incumbent in microbiome drug development that could leverage small intestine access tools to advance its therapeutic pipeline.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/microvitality

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Microvitality